Related Experiment Video
Updated: Jan 18, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type
Ella A Eklund1,2,3, Sama I Sayin1,2,3, Jonas Smith Jonsson1
1Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
Introduction:
Immune checkpoint blockade (ICB) is a standard first-line treatment for stage IV NSCLC without actionable oncogenic alterations. KRAS mutations, prevalent in 30% to 40% lung adenocarcinomas (LUAD) in Western populations, currently lack targeted first-line therapies. This study aimed to assess the predictive value of KRAS mutations for clinical outcomes after distinct ICB regimens, validating our previous findings in a larger cohort with extended follow-up.
Methods:
We conducted a retrospective multicenter study including consecutive stage IV LUAD patients (n = 424) treated with either ICB or platinum-doublet chemotherapy between 2016 and 2021 in Western Sweden. Patient demographics, tumor characteristics, treatment details, and survival outcomes were retrospectively collected from patient charts and the Swedish National Lung Cancer Registry. KRAS mutational status was assessed by next-generation sequencing. Primary end points included overall survival (OS) and progression-free survival (PFS), analyzed using Kaplan-Meier curves and multivariate Cox regression.
Results:
Among 424 patients diagnosed with metastatic LUAD, 40% harbored KRAS mutations (KRAS MUT). KRAS MUT patients exhibited significant improvement in OS (16 versus 8 mo, p < 0.001) and PFS (8 mo versus 5 mo, p < 0.001) with ICB monotherapy. In contrast, KRAS wild-type (KRAS WT) patients derived no survival advantage from ICB monotherapy (OS, 8 mo versus 8 mo, p = 0.648; PFS 4 mo versus 5 mo, p = 0.871) although they did so with chemoimmunotherapy (OS, 15 mo versus 8 mo, p = 0.032; PFS, 6 mo vs 5 mo, p = 0.033). On multivariate analysis, monotherapy was confirmed as an independent factor improving outcomes in KRAS-mutated patients (hazard ratio [HR] 0.533, 95% confidence interval 0.311-0.912, p = 0.018). Finally, we identified KRAS G12C (OS: 13.7 mo versus 10.5 mo, p = 0.0046, PFS: 7.7 mo versus 6.2 mo, p = 0.002) and KRAS G12V (OS: 24.2 mo versus 7.2 mo, p = 0.0204; PFS: 13.7 mo versus 4.5 mo, p = 0.063) but not KRAS G12D (OS, 5.8 mo versus 6.2 mo, p = 0.777; PFS, 4.6 mo versus 3.2 mo, p = 0.694) as distinctly and independently predictive of improved survival after receiving ICB-containing treatment.
Conclusions:
KRAS mutations predict substantial and sustained clinical benefit from first-line ICB monotherapy in metastatic LUAD, whereas KRAS wild-type patients do not. KRAS G12C and KRAS G12V mutations confer improved survival, whereas KRAS G12D does not. Integrating KRAS mutation status into clinical practice could guide personalized treatment strategies, optimizing immunotherapy outcomes in stage IV LUAD.
